Bu1

JP2001247565

AN 2002-068240 [10] WPIX
DNC C2002-020546
TI Use of known glycogen phosphorylase inhibitors in medicaments for the treatment of infections.
DC B02
IN SUTCLIFFE, J A; TREADWAY, J L
PA (PFIZ) PFIZER PROD INC; (SUTC-I) SUTCLIFFE J A; (TREA-I) TREADWAY J L; (PFIZ) PFIZER INC
CYC 34
PI EP-----1149580 A1 20011031 (200210)* EN 27
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
AU---200124871 A 20010913 (200210)
CA-----2339676 A1 20010907 (200210) EN
JP--2001247565 A 20010911 (200210) 25 <--
US--2001046985 A1 20011129 (200210)
KR--2001088417 A 20010926 (200220)
HU---200100973 A2 20020228 (200223)
ZA---200101821 A 20021127 (200305) 45
NZ------510369 A 20030131 (200319)
US-----6555569 B2 20030429 (200331)
ADT EP-----1149580 A1 2001EP-0301555 20010221; AU---200124871 A 2001AU-0024871 20010305; CA-----2339676 A1 2001CA-2339676 20010306; JP--2001247565 A 2001JP-0061661 20010306; US--2001046985 A1 Provisional 2000US-187605P 20000307, 2001US-0785146 20010216; KR--2001088417 A 2001KR-0011636 20010307; HU---200100973 A2 2001HU-0000973 20010306; ZA---200101821 A 2001ZA-0001821 20010305; NZ------510369 A 2001NZ-0510369 20010306; US-----6555569 B2 Provisional 2000US-187605P 20000307, 2001US-0785146 20010216
PRAI 2000US-187605P 20000307; 2001US-0785146 20010216
AN 2002-068240 [10] WPIX
AB EP 1149580 A UPAB: 20020213
NOVELTY - Use of heteroaryl substituted N-(indole-2-carbonyl) amide derivatives (I), their salts and prodrugs in the manufacture of a medicament for treating infection in a mammal is new.
DETAILED DESCRIPTION - Use of heteroaryl substituted N-(indole-2-carbonyl) amide derivatives of formula (I), their salts and prodrugs in the manufacture of a medicament for treating infection in a mammal is new.
dotted line = optional bond;
A = -(CH)=, -C((1-4C alkyl)= or C(halo)= when the dotted line is a bond; or
A = methylene or CH(1-4C alkyl) when the dotted line is not a bond;
R1, R8, R9 = H, halo, 4-, 6- or 7-nitro, CN, 1-4 C alkyl, 1-4C alkoxy, CH2F, CHF2 or CF3;
R2 = H;
R3 = H or 1-5C alkyl;
R4 = H, Me, Et, n-Pr, hydroxy(1-3 C alkyl), (1-3 C)alkoxy(1-3C alkyl), phenyl(1-4C alkyl), phenyl-hydroxy(1-4C alkyl), phenyl(1-4C)alkoxy(1-4C alkyl), thien-2- or -3-yl(1-4C)alkyl or fur-2- or -3-yl(1-4C)alkyl where R4 rings are mono-, di- or tri-substituted on C by

H, halo, 1-4C alkyl, 1-4C alkoxy, CF3, OH, NH2 or CN;
R4 = optionally substituted heterocyclyl or heteroaryl;
R5 = H, OH, F, 1-5C alkyl, 1-5C alkoxy, 1-6C alkanoyl, amino(1-4C alkoxy), mono-N- or di-N, N-(1-4C)alkylamino(1-4C alkoxy), carboxy(1-4C alkoxy), 1-5C alkoxy-carbonyl(1-4C alkoxy), benzyloxy-carbonyl(1-4C)alkoxy or carbonyloxy (the latter being C-C linked with Ph, thiazolyl, imidazolyl, 1H-indolyl, furyl, pyrrolyl, oxazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, or 1,3,5-triazinyl), the preceding R5 rings being optionally mono- or di- substituted by halo, CF3, (1-4 C)alkyl, 1-4C alkoxy, NH2 or OH and the mono or di-substituents are bonded to C;
R7 = H, F or 1-5C alkyl; or
R5+R7 = oxo;
R6 = C(O)R10;
R10 = optionally substituted heteroaryl or heterocyclyl;
R12 = H, Me, Et, n-propyl, hydroxy(1-3C alkyl), (1-3C alkoxy)(1-3C alkyl), phenyl(1-4C)alkyl, phenyl-hydroxy(1-4C alkyl), (phenyl)(1-4C alkoxy-1-4C alkyl), thien-2- or -3-yl(1-4C alkyl) or fur-2- or -3-yl(1-4C alkyl) where R4 rings are mono, di- or tri-substituted on C by H, halo, 1-4C alkyl, 1-4C alkoxy, CF3, OH, NH2, CN, or 4,5-dihydro-1H-imidazol-2-yl; or
R12 = optionally substituted heteroaryl or heterocyclyl or R11-carbonyloxymethyl;
R11 = Ph, thiazolyl, imidazolyl, 1H-indolyl, furyl, pyrrolyl, oxazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl (all optionally mono- or di-substituted by halo, NH2, OH, CF3, 1-4C alkyl, or 1-4C alkoxy and the substituents are bonded to C);
R13 = H, Me, Et, n-propyl, hydroxymethyl or hydroxyethyl;
R14 = C(O)R15;
R15 = optionally substituted heteroaryl or heterocyclyl.
ACTIVITY - Antibacterial; Fungicide; Antiparasitic; Virucide.
In an assay to evaluate inhibition of Chlamydia pneumoniae in Hep-2 cells, compounds of formulae (Ia) and (Ib) had MIC values of 12.5 and 25 micro g/ml, respectively. In a nearly identical protocol to distinguish compounds that interfere with latter stages of C. pneumoniae, and which involved adding the test compounds 15 hours after challenge of Hep-G2 cells with pneumoniae, (Ia) and (Ib) had MIC values of 12.5 and 50 mu g/ml, respectively.
MECHANISM OF ACTION - Glycogen phosphorylase inhibitor.
USE - (I) Are useful in the manufacture of medicaments for treating infections, in particular Chlamydia pneumoniae infection (claimed).